EVX-01 is a personalized, peptide-based cancer immunotherapy targeting metastatic melanoma.

EVX-01 is our personalized cancer immunotherapy intended for the first-line treatment of a variety of metastatic and unresectable cancers amenable to PD-1/-L1 inhibition. Each therapy is designed using our PIONEER platform and will engage each patient's immune system to fight off the cancer by mounting a targeted response against tumors.

In the clinic with EVX-01

Data from the Phase 1/2a clinical trial of EVX-01 has shown that 67% of nine patients benefitted from EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA®) for the treatment of metastatic melanoma, compared to the historical data of only 40% benefiting from a PD-1 inhibitor alone. 22% of the patients in the Phase 1/2a clinical trial achieved a complete response with EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA®)

Phase 2b

In Evaxion's first phase 2b clinical trial, we are evaluating the efficacy and safety of EVX-01. The trial will be conducted globally at clinical sites across the US, Europe, and Australia in collaboration with Merck & Co., Inc., which is supplying the trial with its PD-1 inhibitor, KEYTRUDA®.

Patients enrolled in the phase 2b clinical trial will receive standard of care treatment along with KEYTRUDA® in combination with EVX-01. Evaxion is responsible for the conduct of the trial and Merck will supply the required KEYTRUDA®. Evaxion and Merck will continue to collaborate as the data mature.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Click here to read about the clinical trial.

Cancer illustration stock photo

“With this phase 2b trial, we hope to further validate the promising data generated in our phase 1/2a study, which could pave the way for much needed improvement in the treatment landscape for melanoma and possibly other cancers.”

Complete Elimination of Tumor Following EVX-01 Treatment

Readout from our phase 1/2a clinical study has demonstrated that the EVX-01 therapy in combination with standard of care is well tolerated and able to induce neoantigen-dependent antitumor responses in patients, resulting in elimination or reduction in tumor burden.

Case: The photos above show one of the patients who achieved complete response following EVX-01 treatment.

Before (on the left): Enrollment scan showing the patient with stable disease after 10 months on Anti-PD1 (standard of care), prior to EVX-01 therapy. We can see the tumor marked in the red circle.

After (on the right): Scan following EVX-01 treatment showing complete response (complete elimination of tumor, no sign of cancer). The circle marks where the tumor was before treatment.

Current product candidates

Evaxers working in laboratory


EVX-02 is a novel, DNA-based cancer immunotherapy designed to induce a therapeutic immune response in the adjuvant setting in patients with Stage III and IV resected melanoma.

Evaxers working in laboratory


EVX-03 is innovative, DNA-based neoantigen immunotherapy with an antigen-presenting cell (APC) targeting unit, intended for the treatment of non-small cell lung cancer.